Fundraising FoxTympanogen
Richmond, US · 3 known investors
Find your way into Tympanogen
Sign up to see every warm intro you have to Tympanogen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tympanogen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tympanogen develops Perf-Fix, a gel patch system for nonsurgical eardrum (tympanic membrane) repair that replaces traditional tympanoplasty with a clinic-based procedure. The product is aimed at ENT surgeons and clinicians for outpatient otologic care and is currently in development.
Founders & leadership
Investors · 3
How we know: Citrine Angels's portfolio page · Not right? Tell us
How we know: Cowtown Angels's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 3 rounds · 2021–2025
▶$1.2MraisedMar 2025 · 33 investors · Other TechnologyRule 506(b)
- Elaine Horn-RanneyExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.2M
- Minimum investment
- $10K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25KraisedMay 2023 · 1 investors · Other TechnologyRule 506(b)
- Elaine Horn-RanneyExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMar 2022 · 12 investors · Other TechnologyRule 506(b)
- Elaine Horn-RanneyExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1M
- Minimum investment
- $20K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $3.2M |
| Department of DefenseDefense Health Program | Phase I | 2020 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $1.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Tympanogen do?
- Tympanogen develops Perf-Fix, a gel patch system for nonsurgical eardrum (tympanic membrane) repair that replaces traditional tympanoplasty with a clinic-based procedure. The product is aimed at ENT surgeons and clinicians for outpatient otologic care and is currently in development.
- Who founded Tympanogen?
- Tympanogen was founded by Elaine Horn-Ranney.
- Who are Tympanogen's investors?
- Tympanogen's investors include Citrine Angels, Cowtown Angels, Virginia Venture Partners.
- How much funding has Tympanogen raised?
- Tympanogen has disclosed $2.2M raised across 3 rounds.
- Where is Tympanogen headquartered?
- Tympanogen is headquartered in Richmond, US.